The biotech industry continues to be in something of a “hangover period” where everyone realizes that there was “probably just a little bit too much enthusiasm” in circa 2020 and 2021, said Matthias Kleinz, DVM, Ph.D., executive vice president, translational sciences at UPMC Enterprises, the innovation and commercialization arm of University of Pittsburgh Medical…